Baseline Clinical and Functional Spectrum of Idiopathic Pulmonary Fibrosis Patients in a Fully Enrolled Global Phase 2 Trial of the PRS Inhibitor Bersiporocin (ERS 2026) - May 30, 2026 - Abstract #PA828; Pres time: Sep 6, 2026; 08:00 AM - 09:30 AM; Location: PS-34; Board Number: 5; P2 | "Participants were randomized 2:1 to receive bersiporocin 150 mg twice daily or placebo for 24 weeks and stratified by background antifibrotic use (pirfenidone or nintedanib vs no antifibrotics). In this fully enrolled Phase 2 trial of bersiporocin, mean baseline FVC was numerically higher in patients not receiving background antifibrotics. Similar trends have been noted in recent IPF trials by baseline antifibrotic use. These baseline data provide context for planned subgroup interpretation of efficacy and safety outcomes by treatment status."
Clinical • P2 data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
M. Park; M. Chung; W. Choi; H. Lee; K. Gibson; E. Belloli; M. Ramaswamy; T. Kaelin; A. Nambiar; S. Nathan; T. Maher; J. Ryu; Y. Kwak; J. Song
|